BioMarin Grabs Plant From Pfizer

Xconomy San Francisco — 

BioMarin Pharmaceutical (NASDAQ: BMRN) of Novato, CA plans to buy a biotech manufacturing facility in Ireland that’s owned by New York-based Pfizer (NYSE: PFE), according to a press release. BioMarin will purchase the plant for $48.5 million—roughly a fifth of what it would have paid to build a facility like it from scratch. BioMarin will use the plant to make its treatment for Morquio A Syndrome, now in Phase 3 trials, and expects the facility to be licensed by 2015.